Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Immune Checkpoint Inhibitors & Immune-Related Adverse Events

Priya Chokshi, MD, Roberta Seidman, MD, Noah Levit, PhD, MD, & Steven E. Carsons, MD  |  Issue: September 2018  |  September 20, 2018

This case also poses a difficult question for patients and oncologists regarding how they will manage ICI use once an irAE occurs. When an adverse event occurs during ICI therapy, it is important to ascertain if it is from disease progression, an unrelated event or treatment-related irAE. Characterizing these toxicities, even if uncommon, is important.

Management of irAEs is under intense investigation at this point, but general guidelines are being developed. No clear data exist on when to stop ICI therapy or when to reintroduce an ICI once the autoimmune process is managed with steroids for control of responsive cancers.

Figure 3: Management Algorithm for Immune-Related Adverse Events (irAEs) Associated with Checkpoint Inhibitor Use (Adapted)

(click for larger image) Figure 3: Management Algorithm for Immune-Related Adverse Events (irAEs) Associated with Checkpoint Inhibitor Use (Adapted)

In the long term, it is unclear how the patient’s underlying immunologic makeup is affected after the use of ICIs or after the development of an autoimmune condition. Further, predictive biomarkers or antibodies that would help identify which patients and organ systems are at risk for immune-mediated toxicity would help target cancer therapy (see Figure 3).2,3,5,25

Immune-related adverse events can involve any organ system, but myalgias, arthralgias, gastrointestinal, dermatologic, hepatic & endocrine autoimmune effects are those most commonly reported with nivolumab use.

Conclusion

This patient had a cardiac history, was on statin therapy and had ovarian cancer treated with the PD-1 inhibitor nivolumab. She developed life-threatening immune-mediated adverse events, including cardiac toxicity, myositis, myasthenia-like syndrome, pulmonary compromise, rash and gastro­intestinal toxicity mimicking auto-inflammatory rheumatologic conditions. Immune checkpoint inhibitors have high response rates and overall better tolerance compared with chemotherapy. However, with their increased and broadening uses, it is becoming evident they have a unique inflammatory toxicity innate to the way they affect the immune system with variable presentations. It will be especially important to monitor malignancies often associated with para­neoplastic autoimmune responses themselves in trying to differentiate toxicity of the treatment from manifestation of the cancer.

The questions raised and the management of affected patients requires an interdisciplinary approach. Rheumatologists, oncologists and all subspecialties will need to become familiar and adept at rapidly recognizing and managing irAEs because checkpoint inhibitor use is becoming increasingly prevalent and will likely become the future of cancer therapy.


Priya Chokshi, MD, is a second-year rheumatology fellow at NYU Winthrop Hospital in New York and will be pursuing a career in academic rheumatology.

Roberta Seidman, MD, is an associate professor of pathology at Stony Brook Medical Center in New York. She is board certified in both neuropathology and neurology and has more than 30 years’ experience in evaluation of nerve and muscle biopsies and brain autopsy specimens.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 7 8 9 10 | Single Page
Share: 

Filed under:ConditionsDrug UpdatesMyositisOther Rheumatic Conditions Tagged with:immune-related adverse eventsirAEsmyositisnivolumab

Related Articles
    Lightspring/shutterstock.com

    The Immune Checkpoint Inhibitors Unleashed to Fight Cancer

    May 17, 2017

    A 53-year-old female presented to the clinic for severe polyarticular joint pain and was found to have a seronegative inflammatory arthritis. Six months before, she had completed 10 months of treatment for stage IV metastatic melanoma with the immune checkpoint inhibitors, nivolumab and ipilimumab, achieving complete remission of her cancer. She said that throughout her…

    Alpha Tauri 3D Graphics / shutterstock.com

    Rheumatic Complications from Immune Checkpoint Inhibitors

    December 16, 2021

    Immune checkpoint inhibitors (ICIs), such as anti-programmed cell-death 1/programmed death-ligand 1 (anti-PD-1/PD-L1) or anti-CTL-associated protein (anti-CTLA-4), have dramatically changed the treatment of advanced cancers over the past decade. ICIs block T cell inhibition, thus increasing the anti-tumor immune response. ICIs are used not only for metastatic cancer, but also as adjuvant treatment for some stage…

    Nivolumab-Induced Arthritis

    October 18, 2018

    Immune checkpoint inhibitors (ICIs) are increasingly used to treat a variety of malignancies, leading to better cancer treatment outcomes and patient survival. However, the emergence of autoimmunity has been a major adverse event resulting from ICI use. Below, we describe a patient who experienced a flare of preexisting psoriasis and new-onset severe psoriatic arthritis after…

    ACR Convergence graphic

    Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors

    December 4, 2020

    Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences